Who are AN2690, 2.5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TELMINUVO Tab. (80/2.5mg), TEV-56248, VTS-K, USL255, TV-46000, SHR6390 Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/an2690-2-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AN2690, 2.5% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AN2690, 2.5% (AN2690, 2.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sodium-activated potassium channel inhibitor. Area: Neurology.

phase 2 sodium-activated potassium channel inhibitor KCNN4 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AN2690, 2.5% (AN2690, 2.5%) — Pfizer. AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AN2690, 2.5% TARGET	AN2690, 2.5%	Pfizer	phase 2	sodium-activated potassium channel inhibitor	KCNN4
TELMINUVO Tab. (80/2.5mg)	TELMINUVO Tab. (80/2.5mg)	Chong Kun Dang Pharmaceutical	phase 3	Sodium-activated potassium channel inhibitor	KCNN4
TEV-56248	TEV-56248	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	sodium-activated potassium channel inhibitor	KCNN4
VTS-K	VTS-K	Maimonides Medical Center	marketed	sodium-activated potassium channel inhibitor	Nav1.6
USL255	USL255	Upsher-Smith Laboratories	phase 3	sodium-activated potassium channel inhibitor	Nav1.5
TV-46000	TV-46000	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
SHR6390 Tablets	SHR6390 Tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sodium-activated potassium channel inhibitor class)

Aurobac Therapeutics SAS · 1 drug in this class
Kasr El Aini Hospital · 1 drug in this class
Maimonides Medical Center · 1 drug in this class
Pfizer · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
Upsher-Smith Laboratories · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AN2690, 2.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/an2690-2-5. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing